The FDA has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for people with severe asthma.
Indiana University School of Medicine researchers are taking a closer look at how young patients respond to biologic ...
The U.S. health regulator has approved GSK's add-on treatment for severe asthma, offering a less frequently dosed option, but ...
MedPage Today on MSN
First Twice-Yearly Biologic Approved for Severe Eosinophilic Asthma
The FDA approved depemokimab (Exdensur) as the first ultra-long-acting biologic with twice-yearly dosing approved for ...
With a fresh endorsement from the FDA, the last of five major drug approvals has fallen into place for GSK in 2025. | Tuesday ...
Depemokimab-ulaa (Exdensur) is approved for severe asthma with an eosinophilic phenotype, offering protection with just two ...
The MHRA has approved depemokimab as an add-on treatment for severe asthma and chronic rhinosinusitis with nasal polyps.
The Food and Drug Administration (FDA) has approved Exdensur (depemokimab-ulaa), an interleukin-5 antagonist, for add-on maintenance treatment of severe asthma characterized by an eosinophilic ...
Winter woes like blocked noses and breathing trouble for asthma and sinus sufferers may find relief with turmeric. Its potent ...
Among seven new medicines recommended for approval by the EMA's human medicine advisory committee at its latest meeting is ...
A monthly injection for managing severe asthma could help patients safely reduce or even discontinue daily steroid ...
The FDA has approved GSK’s Exdensur (depemokimab-ulaa) as an add-on maintenance therapy for adolescents and adults with severe asthma characterized by an eosinophilic phenotype. 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback